This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Shire Pharmaceuticals Group PLC

Drug Names(s): Carrierwave triiodothyronine (T3) hormone

Description: NRP409 (Carrierwave triiodothyronine (T3) hormone) is being developed as a replacement or supplemental therapy in patients with primary hypothyroidism and other indications. Thyroid hormone replacement therapies (HRTs) are based on tetraiodothyronine (T4), and require deiodination within the patient to convert to the more active hormone (T3). Patients demonstrate significant variability in their ability to convert the T4 hormone in the HRT into T3. This variability can arise as a function of age, stress or a variety of medical conditions. Commercially approved drugs based on T3, however, engender certain safety risks, most notably cardiovascular in nature. NRP409 is designed to reduce the variability and safety risks of T3. The Carrierwave technology involves attaching an active pharmaceutical ingredient to an adjuvant, such that activity of the drug requires enzymatic removal of the adjuvant in the body.

Deal Structure: On April 20, 2007, Shire announced that it completed its acquisition of New River Pharmaceuticals pursuant to a short-form merger in which a subsidiary of Shire was merged with and into New River with New River continuing as the surviving corporation.

Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

In October 2014, AbbVie and Shire have agreed to terminate their proposed merger following the decision by AbbVies Board to withdraw support for the proposed transaction. The Companys decision was based upon its assessment of the September 22, 2014 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions.

NRP409 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug